The DifferenceBetween IHC and FISH in Detecting HER2 Protein Expression and Gene Amplification in Breast Cancer
Objective To conduct comparison of immunohistochemistry (IHC ) and fluorescence in situ hybridization (FISH)for human epidermal growth factor receptor 2 (HER2 )detection in breast cancer patients.Methods We selected a cohort of 158 breast cancer patients who received treatment at our hospital from February,2019 to January,2022.We utilized IHC and FISH techniques to identify the protein expression and gene amplification of HER2.We subsequently scrutinized the outcomes of these two methods and evaluated their concurrence.Results According to the results of immunohistochemistry (IHC ) and fluorescence in situ hybridization (FISH)tests on 158 patients,3.16％(5)had HER2(1+),61.39％(97)had HER2(2+),and 35.44％(56 )had HER2 (3+).Among these patients,46.20％(73 )showed HER2 amplification,while 53.80％(85)did not.The negative concordance rate for all FISH tests was 100％.FISH tests for all HER2 (3+)patients confirmed amplification with a positive concordance rate of 100％.In addition,17 out of 97 HER2(2+)patients showed amplification by FISH,with a positive concordance rate of 17.52％.The agreement between the two methods for detecting HER2 was acceptable and statistically significant(Kappa value=0.775,P<0.05).Conclusion The consistency between the IHC and FISH methods is good.Genetic testing methods can be selected according to the actual situation to guide clinical treatment.
万方数据
维普
